Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer

Gynecologic Oncology

Volumn 94, Issue 3, 2004, Pages 719-724

  Micha, John P ^a,b   Goldstein, Bram H ^a   Rettenmaier, Mark A ^a   Mattison, Julie ^a   Graham, Cheri ^a   Birk, Connie L ^a   Brown, John V ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Gynecologic Oncology Associates   (United States)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Gynecologic oncology; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; COLONY STIMULATING FACTOR; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; GRANISETRON; LORAZEPAM; ONDANSETRON; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; NEUTROPENIA; OUTPATIENT; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PILOT PROJECTS;

EID: 4444228249     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.050     Document Type: Article

References (28)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics 2001. CA Cancer J. Clin. 51:2001;15-36
2. Hansen S.W. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin. Oncol. 29(1 Suppl. 1):2002;17-19
3. Poole C.J., Jordan S.D., Higgins H.B., et al. A phase I intra & interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;220a. (abstr 878)
4. Kaufmann M., von Minckwitz G. Gemcitabine in ovarian cancer: an overview of safety and efficacy. Eur. J. Cancer. 33:1997;31-33
5. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:1995;72-79
6. Krakowski I., Petit T., Kayitalire L., Weber B., Beaudouin M., Canon J.L., et al. Gemcitabine in combination with cisplatin in advanced ovarian cancers (AOC): a phase II study. Proc. Am. Soc. Clin. Oncol. 17:1998;356a
7. Nogue M., Cirera L., Arcusa M., Tusquets I., Batiste-Alentorn E., Font A., et al. Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;357a
8. Nogue M., Cirera L., Arcusa A., Batiste-Alentorn E., Balil A., Font A., et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs. 13:2002;839-845
9. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst. 86:1994;1530-1533
10. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63:1996;89-93
11. Kudelka A.P., Verschraegen C.F., Edwards C.L., Freedman R.S., Plunkett W., Ruiz van Haperen V.T., et al. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proc. Am. Soc. Clin. Oncol. 17:1998;367a
12. Underhill C., Parnis F.Z.X., Highley M., Ahern J., Lund B., Dombernowsky P., et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol. 15:1996;290a
13. Greco F.A., Burris H.A., Hainsworth J.D. Gemcitabine, paclitaxel, and carboplatin for advanced non-small cell lung cancer. Oncology. 14(Suppl. 4):2000;31-34
14. Brown J.V., Rettenmaier M.A., Dillman R.A., Birk C.L., Culkin K., Micha J.P. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol. Oncol. 68:1998;166-168
15. Hainsworth J.D., Greco F. Paclitaxel administered by 1-hour infusion. Cancer. 74:1994;1377-1382
16. Calvert A.H., Newell D.R., Gunbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756
17. Jelliffe R.W. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79:1973;605
18. World Health Organization WHO handbook for reporting results for cancer treatment. 1979;World Health Organization, Geneva
19. Rustin G.J., Marples M., Nelstrop A.E., Mahmoudi M., Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19:2001;4054-4057
20. Rossel R., Tonato M., Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin. Oncol. 25(Suppl. 9):1998;27-34
21. Kosmidis P. Paclitaxel/Carboplatin vs. Paclitaxel/Gemcitabine in advanced non-small cell lung cancer. Oncology. 7(Suppl. 4):2000;41-48
22. Ten Bokkel Huinink W., Veenjof C., Huizing M., Rodenhuis S., Helmerhorst T., Dubbelman R., et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin. Oncol. 24:1997;S2-31-S2-33
23. Markman M., Liu P.Y., Wilczynski S., Monk B.J., Copeland L., Alberts D. Phase 3 randomized trial of 12 versus 3 months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group trial. Gynecol. Oncol. 84:2002;479
24. Barakat R., Alomadrones L., Venkatraman E., Aghajanian C., Brown C., Shapiro F., et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol. Oncol. 69:1998;17-22
25. Gordon A.N., Stringer C.A., Matthews C.M., Willis D.L., Nemunaitis J. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J. Clin. Oncol. 15:1997;1965-1973
26. Ozols R.F., Markman M., Thigpen J.T. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet. 360:2002;505-515
27. de Jongh F.E., de Wit R., Verweij J., Sparreboom A., van den Bent M.J., Stoter G., van der Burg M.E. Dose-dense cisplatin/paclitaxel. A well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur. J. Cancer. 38:2002;2005-2013
28. Thigpen T. The role of gemcitabine based doublets in the management of ovarian carcinoma. Semin. Oncol. 29(1 Suppl. 1):2002;11-16